NFE2L2 and hepatocellular carcinoma: The pH-responsive nanocarrier HDP co-delivers sorafenib and siNRF2 to overcome NRF2-mediated ferroptosis resistance, significantly enhancing anti-tumor effects in hepatocellular carcinoma.